Abstract: An integrated biomarker system for evaluating a risk of impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM) for the first time is disclosed. The integrated biomarker system includes quantitative determination results of L-glutamine, L-valine, L-leucine, L-lysine, L-proline, L-phenylalanine, L-arginine, L-glutamic acid, L-isoleucine, L-methionine, L-carnitine, acetyl-L-carnitine, lysophosphatidyl choline (LPC (P-16:0)), LPC (17:0), LPC (14:0) and propionyl-L-carnitine in a sample. The integrated biomarker system for IFG and T2DM of subject serum sample contains a correlative biomarker group on a biological network path to reflect the overall metabolic characteristics information of IFG and T2DM and to avoid that characteristic information of a disease cannot be reflected integrally and completely due to single or separate analysis of a biomarker.